Market Closed -
Bombay S.E.
11:00:49 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
208
INR
|
-3.08%
|
|
-5.63%
|
-2.30%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,101
|
2,722
|
2,205
|
2,575
|
8,585
|
10,735
|
Enterprise Value (EV)
1 |
5,856
|
3,562
|
3,225
|
3,263
|
9,180
|
11,533
|
P/E ratio
|
45.3
x
|
-25.3
x
|
8.9
x
|
7.22
x
|
11.8
x
|
18.9
x
|
Yield
|
-
|
-
|
0.73%
|
1.53%
|
0.54%
|
0.43%
|
Capitalization / Revenue
|
2.43
x
|
1.48
x
|
1.09
x
|
1.12
x
|
2.18
x
|
3.03
x
|
EV / Revenue
|
2.8
x
|
1.94
x
|
1.6
x
|
1.41
x
|
2.33
x
|
3.25
x
|
EV / EBITDA
|
23.3
x
|
156
x
|
9.13
x
|
6.68
x
|
9.69
x
|
17.3
x
|
EV / FCF
|
-35.7
x
|
-106
x
|
-12.8
x
|
14.7
x
|
651
x
|
-46.8
x
|
FCF Yield
|
-2.8%
|
-0.95%
|
-7.79%
|
6.82%
|
0.15%
|
-2.14%
|
Price to Book
|
3.02
x
|
1.72
x
|
1.2
x
|
1.18
x
|
2.99
x
|
3.16
x
|
Nbr of stocks (in thousands)
|
91,727
|
91,809
|
91,880
|
91,880
|
92,003
|
92,028
|
Reference price
2 |
55.61
|
29.64
|
24.00
|
28.03
|
93.32
|
116.6
|
Announcement Date
|
17/07/18
|
01/08/19
|
06/09/20
|
25/08/21
|
26/08/22
|
16/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,095
|
1,838
|
2,016
|
2,307
|
3,946
|
3,543
|
EBITDA
1 |
251
|
22.79
|
353.4
|
488.8
|
947.1
|
666.9
|
EBIT
1 |
176.8
|
-57.11
|
273.8
|
409.5
|
861.6
|
569.6
|
Operating Margin
|
8.44%
|
-3.11%
|
13.58%
|
17.75%
|
21.83%
|
16.07%
|
Earnings before Tax (EBT)
1 |
113.4
|
-126
|
268.7
|
413.3
|
952.6
|
725.1
|
Net income
1 |
113
|
-107.4
|
247.8
|
357
|
728.8
|
569
|
Net margin
|
5.39%
|
-5.85%
|
12.29%
|
15.48%
|
18.47%
|
16.06%
|
EPS
2 |
1.228
|
-1.170
|
2.697
|
3.884
|
7.907
|
6.173
|
Free Cash Flow
1 |
-164
|
-33.72
|
-251.1
|
222.5
|
14.11
|
-246.5
|
FCF margin
|
-7.83%
|
-1.84%
|
-12.46%
|
9.64%
|
0.36%
|
-6.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
45.51%
|
1.49%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
62.31%
|
1.94%
|
-
|
Dividend per Share
|
-
|
-
|
0.1750
|
0.4300
|
0.5000
|
0.5000
|
Announcement Date
|
17/07/18
|
01/08/19
|
06/09/20
|
25/08/21
|
26/08/22
|
16/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
755
|
840
|
1,020
|
688
|
595
|
798
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.009
x
|
36.85
x
|
2.886
x
|
1.408
x
|
0.6278
x
|
1.197
x
|
Free Cash Flow
1 |
-164
|
-33.7
|
-251
|
222
|
14.1
|
-246
|
ROE (net income / shareholders' equity)
|
6.99%
|
-6.58%
|
14.5%
|
17.8%
|
28.8%
|
18.2%
|
ROA (Net income/ Total Assets)
|
3.72%
|
-1.15%
|
5.16%
|
7.1%
|
13.5%
|
7.56%
|
Assets
1 |
3,037
|
9,320
|
4,807
|
5,030
|
5,407
|
7,527
|
Book Value Per Share
2 |
18.40
|
17.20
|
19.90
|
23.80
|
31.20
|
36.90
|
Cash Flow per Share
2 |
0.4900
|
0.1900
|
0.3600
|
2.070
|
2.200
|
1.360
|
Capex
1 |
96.1
|
56.3
|
58.1
|
180
|
206
|
287
|
Capex / Sales
|
4.58%
|
3.07%
|
2.88%
|
7.82%
|
5.23%
|
8.11%
|
Announcement Date
|
17/07/18
|
01/08/19
|
06/09/20
|
25/08/21
|
26/08/22
|
16/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -2.30% | 237M | | +18.67% | 43.74B | | +21.99% | 22.26B | | +16.41% | 14.9B | | +9.03% | 13.39B | | +40.48% | 12.12B | | -9.64% | 6.92B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.47B |
Generic Pharmaceuticals
|